US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Xiaomi Shares Jump on Europe EV Expansion Plan 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
France Targets Shein, Temu With Fast-Fashion Fees 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Milei Threatens Falkland Oil Firms With Sanctions 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
DUBLIN, Ireland, March 07, 2018 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its senior management team will present and participate in the Barclays Global Healthcare Conference March 14th at 8:00 AM ET in Miami, FL.
A live webcast of the company presentation can be accessed through the Investors section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Prothena’s pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004). The Company continues to advance additional discovery programs against targets including tau, Aβ (Amyloid beta) and ALECT2 where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company's website at www.prothena.com.
Media & Investor Contact:
Ellen Rose, Head of Communications
650-922-2405, [email protected]
